Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remodulin Transition from Flolan in PAH
NCT00058929Phase 4Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Oct 2002
- Primary completion
- Aug 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Remodulin with Placebo (2 arms). Primary endpoint: Time to clinical deterioration at 8 weeks. Started Oct 2002; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00058929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058929.